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Abstract
Background: Recent whole genome analysis and follow-up studies have identified many new risk variants for coeliac 
disease (CD, gluten intolerance). The majority of newly associated regions encode candidate genes with a clear 
functional role in T-cell regulation. Furthermore, the newly discovered risk loci, together with the well established HLA 
locus, account for less than 50% of the heritability of CD, suggesting that numerous additional loci remain 
undiscovered. Linkage studies have identified some well-replicated risk regions, most notably chromosome 5q31 and 
11q23.
Methods: We have evaluated six candidate genes in one of these regions (11q23), namely CD3E, CD3D, CD3G, IL10RA, 
THY1 and IL18, as risk factors for CD using a 2-phase candidate gene approach directed at chromosome 11q. 377 CD 
cases and 349 ethnically matched controls were used in the initial screening, followed by an extended sample of 171 
additional coeliac cases and 536 additional controls.
Results: Promotor SNPs (-607, -137) in the IL18 gene, which has shown association with several autoimmune diseases, 
initially suggested association with CD (P < 0.05). Follow-up analyses of an extended sample supported the same, 
moderate effect (P < 0.05) for one of these. Haplotype analysis of IL18-137/-607 also supported this effect, primarily due 
to one relatively rare haplotype IL18-607C/-137C (P < 0.0001), which was independently associated in two case-control 
comparisons. This same haplotype has been noted in rheumatoid arthritis.
Conclusion: Haplotypes of the IL18 promotor region may contribute to CD risk, consistent with this cytokine's role in 
maintaining inflammation in active CD.
Background
Coeliac disease (CD), or gluten intolerance is an autoim-
mune inflammatory condition of the small bowel, precip-
itated by gluten and related proteins from dietary grains
such as wheat, barley and rye. Removal of these proteins
from the diet is usually sufficient for complete remission
of symptoms. The primary genetic determinant of CD
risk is inheritance of the HLA-DQ2 molecule, encoded by
genes (HLADQA1  and  HLADQB1) on chromosome
6p21. However, other genetic risk factors are known to
exist, a number of which have been identified by linkage
studies [1-3] or, more recently, whole genome SNP analy-
ses [4,5].
Several genomic regions thought to harbour suscepti-
bility genes have been identified by family studies. Link-
age of several of these regions to CD has been replicated
in independent studies from multiple populations. Of
these, chromosomal regions 5q31 and 11q23 have been
most successfully replicated. The linkage of 11q markers
to coeliac disease have been demonstrated by 3 studies
[1-3]. Markers from 115.8 Mb (D11S4111) to 123.6
(D11S4464) have shown linkage, with peak associations
at D11S4142 at chromosome position 115.3 Mb [2], and
D11S4464 at 123.6 Mb [3].
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This region harbours several candidate genes for CD
susceptibility. Louka et al [6] reported no association
between CD and functional polymorphisms in the
MMP1  and  MMP3  genes. However, Mora et al [7]
reported a sex specific association between an MMP3
promotor polymorphism and coeliac disease.
The CD3 genes (118.2 Mb), CD3-epsilon (CD3E), CD3-
delta (CD3D) and CD3-gamma (CD3G), lie within 50 kb
of each other in this region, forming part of the T-cell-
receptor (TCR) complex. This complex consists of either
alpha and beta or gamma and delta variant chains, in
association with the invariant chains CD3E,  CD3D,
CD3G and CD3-zeta (CD3Z). During development, this
CD3 protein complex plays an important role in the tran-
s i t i o n  o f  t h ym ocyt e s  fr o m  i m m a t u r e  p r ecu r so r s  t o  t h e
final mature CD4+ or CD8+ single-positive T-cell. Stud-
ies have shown that the CD3 components are essential
during the early stages of human thymopoiesis and defi-
ciencies in these genes have been linked with severe com-
bined immunodeficiency [8,9]. One preliminary study
has been carried out to date on the association between
CD3 and autoimmune disease [10], which identified a sig-
nificant association between CD3D and type 1 diabetes
with the use of microsatellites.
Also located on 11q23 is the THY1 gene (119.2 Mb).
This gene encodes a major cell surface glycoprotein char-
acteristic of T-cells and is a member of the immunoglob-
ulin supergene family. Although the role of this protein is
not fully elucidated, its position as a cell surface molecule
on T-cells and its involvement in cell-cell interactions
[11] make it a candidate gene for coeliac disease patho-
genesis.
The IL10RA gene (117.9 Mb) encodes the interleukin
10 receptor-alpha chain of the IL-10 receptor complex.
This molecule is the receptor for IL10, an anti-inflamma-
tory cytokine produced by a subset of activated T-cells,
B-cells and macrophages, which has a role in a variety of
immunoregulatory functions [12]. Genetic variants of
IL10RA  have been shown to inhibit the production of
TNF-alpha [13], a protein known to play a role in coeliac
disease. Coeliac patients in remission produce signifi-
cantly higher levels of TNFa than controls and while this
appears to be a genetically inherited trait, it does not
appear to be due solely to genetic variation at the TNF
locus[14] [Daly and McManus, unpublished observation].
Thus, polymorphisms at other loci which could alter TNF
production are high priorities for investigation as candi-
date genes.
A polymorphism in IL10 (-1087) has been linked to a
number of autoimmune diseases including inflammatory
bowel disease, rheumatoid arthritis (RA) and systemic
lupus erythematosus [15]. A significant association
between the IL10-1087 polymorphism and coeliac dis-
ease has been shown [16]. However, this association
failed to be replicated in subsequent work [17]. The IL10-
1087 polymorphism has also been shown to be associated
with differing levels of IgA anti-endomyseal and anti-tis-
sue transglutaminase antibodies in CD patients [16],
while recombinant human interleukin 10 has been shown
to suppress gliadin dependent T-cell activation in ex vivo
cultured coeliac intestinal mucosa [18]. These observa-
tions suggest that IL10 may be a factor in the pathogene-
sis of CD. However, as IL10 signals through the specific
receptor, IL10RA, a possible role for this receptor mole-
cule in disease, mediated through the IL10  pathway,
should also be considered. The strength of IL10RA as a
candidate gene is enhanced by its physical proximity to
D11S976, a microsatellite marker which has been high-
lighted in a number of family studies as showing linkage
with CD.
Also present as a candidate gene in this region is IL18
(112.0 Mb), also known as interferon-gamma-inducing
factor. Though this gene, located at chromosomal posi-
tion 11q22.2-22.3, is some distance from the major link-
age peaks in the region, it may still fall within the region
of linkage as it is located between a marker shown to be
linked to disease (D11S4111) at position 115.8 MB and
the next tested marker (D11S898) at 101.0 MB which was
not linked to disease [2]. IL18  is a proinflamatory
cytokine which, in synergy with IL12, promotes develop-
ment of the Th1 lymphocyte response by induction of γ-
interferon (IFN-γ). The latter is highly produced in CD
lesions, and is known to play an important role in inflam-
matory and infectious diseases [19]. Furthermore,
increased serum levels of IL18 have been identified in
patients with autoimmune diseases such as RA [20] and
acute asthma [21]. Two polymorphisms in the promoter
region of the gene have shown evidence of altering IL18
protein expression. One polymorphism located at posi-
tion -607 has been found to disrupt a potential cAMP-
response element protein-binding site, while the other at
position -137 alters a consensus H4TF-1 nuclear factor-
binding site. Multiple sclerosis patients homozygous for
the -607C and -137G alleles have higher levels of IL18
mRNA compared to other diplotypes, suggesting that
these polymorphisms do indeed regulate activity of the
gene [22]. More recent results point to a haplotypic effect
based on other polymorphisms [23]. Numerous genetic
association studies have been carried out on these SNPs
and others in the gene, to investigate if any association
exists with various autoimmune diseases. Significant
association has been shown between IL18 and type 1 dia-
betes [24], Crohn's disease [25], atopic eczema [26],
inflammatory bowel disease [27], and asthma [28]. Other
studies have failed to find a disease association between
IL18 and several diseases, among which are studies on
coeliac disease [29], RA [30], type 1 diabetes [31-33], and
periodontitis [34]. A recent study, which included analy-Brophy et al. BMC Medical Genetics 2010, 11:76
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sis of the Irish samples analysed in this study, has identi-
fied functional genetic variants at IL18RAP, a receptor for
IL18, as a risk factor in coeliac disease [35].
Here we report candidate gene analysis of the above
genes, using a haplotype tagging approach to maximise
coverage of the common genetic variants in European
po pula t ions.  In a ddit io n t o t he  a nal yses perf orm ed f or
this study, we also tested for epistatic effects between
IL18 and IL18RAP.
Methods
377 biopsy-confirmed unrelated coeliac patients and 349
controls were used as an initial screening population. All
controls were healthy, randomly selected blood donors,
and all case and control subjects were of uniform Irish
ancestry. Sample characteristics are summarised in Table
1. Informed consent was obtained from all study subjects
and the study was approved by the Ethics Committees of
St James's Hospital, Dublin and the Mater Misericordiae
University Hospital, Dublin. 10% of samples were re-gen-
otyped anonymously in order to evaluate error rates.
SNPs with an uncorrected P value < 0.05 on the initial
screen were then tested on an additional sample of 171
coeliacs and 536 controls and the data pooled. Coeliac
samples are biopsy proven, the significant majority (>
80%) of which have the severe phenotype (Marsh III or
greater) at the time of biopsy. In the absence of clear dam-
age to the villous architecture, patients are diagnosed on
the basis of an IEL infiltrate and or crypt hyperplasia
(Marsh I/II) AND positivity for antibody tests (both anti-
EMA and anti-tTG) and where possible, evidence of clin-
ical improvement on a gluten free diet. HLA-DQB1 test-
ing of approximately 300 patients shows over 99% are
positive for one or more of the known HLA-DQB1 alleles,
HLA-DQB1*0201/0202/0301/0302.
In order to optimise genotyping efficiency, haplotype
tags were identified for each gene. IL10RA and IL18 hap-
lotype tags were identified from complete, or near com-
plete, phased re-sequence data from SeattleSNPs http://
pga.gs.washington.edu/education.html and Innate
Immunityhttp://www.pharmgat.org/IIPGA2/index_html
databases. Re-sequence data were not available for the 3
CD3  genes or THY1. For these, genotype data were
downloaded from the NCBI and Perlegen databases and
gametic phase was assigned. Haplotype tags for each of
the above genes were identified using the SNPtagger pro-
gram, in order to tag common haplotypes (> 5%) for SNPs
with minor allele frequency > 0.05. Genotyping was per-
formed using Amplifluor™ or Taqman™ technology. Tests
for allele and haplotype frequency heterogeneity were
performed using HITAGENE,  GENEPOP[36],  HAP-
LOSTATS[37] and PHASEv2 [38]. Tests for gene-gene inter-
action were performed using PLINK[39].
Results
All loci conformed to Hardy-Weinberg Equilibrium (P >
0.05) in all populations, with the exception of CD3E
rs1945764 in control population 1 (P = 0.042). Anony-
mous genotype duplication suggested an error rate < 1%.
Patterns of linkage disequilibrium (LD) are presented in
S u p p l e m e n t a ry  F i g u r e  S 1  ( A d d i t i o n a l  F i l e  1 ) .  A l l  po l y -
morphic sites in IL10RA, CD3D, CD3E, CD3G, THY1 and
IL18 were analysed for allelic, genotypic and carrier sta-
tus association with disease individually and results are
summarised in Table 2. No polymorphism within the
IL10RA, CD3D, CD3E, CD3G or THY1 genes were found
to be significantly associated with disease in this study. In
the initial phase, two polymorphisms in the IL18 gene
(IL18-137 rs187238 and IL18-607 rs1946518) showed a
significant association with disease prior to correction for
multiple testing. IL18-137  was significantly associated
with disease (genotype frequency heterogeneity, P =
0.0380, Table 2). IL18-607 also showed a significant asso-
ciation with disease status (genotype frequency heteroge-
neity, P = 0.005; carrier status for the major allele, P =
0.001, Odds Ratio = 1.955 [CI, 1.30-2.95]).
These polymorphisms were further investigated in an
augmented sample with 171 additional coeliacs and 536
random controls from the Irish Blood Transfusion Ser-
vice (Table 2). These controls were compared with coeli-
acs separately and as a single pooled population, bringing
the total number of control samples to 885. Comparison
of the pooled coeliac sample with pooled control samples
suggested a moderate effect for IL18-607, though it was
w e a k e r  t h a n  t h a t  o b s e r v e d  f o r  c o e l i a c  1  V s  c o n t r o l  1
(Table 2). In addition, tests for epistasis using PLINK soft-
ware did not suggest any interaction between these IL18
and IL18RAP genes in coeliac disease susceptibility.
Haplotype analysis (Table 3) of the IL18-607/-137 sup-
p o r t e d  t h i s  m o d e r a t e  e f f e c t  o v e r  a l l  h a p l o t y p e s  ( P  <
Table 1: Sample sizes, age and sex for cases and controls.
N%  F e m a l e A g e  ( m e a n ) S D
Coeliac 1 377 71 50.3 14.2
Coeliac 2 171 68 44.5 15.5
Control 1 349 57 32.6 8.5
Control 2 536 69 35.6 12.4Brophy et al. BMC Medical Genetics 2010, 11:76
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Table 2: Comparison of genotypic frequencies (%) between Coeliac and Control samples (Table 1) and the pooled Coeliac 
(1 + 2) and Control (1 + 2) samples.
A1A1 A1A2 A2A2 p
Coeliac 1 Vs Control 1
IL10RA Coeliac 1 86 (23.1) 192 (51.8) 93 (25.1)
rs2256111 A/G Control 1 69 (19.8) 192 (55.0) 88 (25.2) 0.514
IL10RA Coeliac 1 255 (68.0) 101 (26.9) 19 (5.1)
rs4252272 A/G Control 1 226 (64.8) 115 (33.0) 8 (2.3) 0.068
IL10RA Coeliac 1 171 (45.4) 169 (44.8) 37 (9.8)
rs2229113 G/A Control 1 150 (43.7) 167 (48.7) 26 (7.6) 0.426
IL10RA Coeliac 1 113 (30.3) 191 (51.2) 69 (18.5)
rs9610 G/A Control 1 96 (28.0) 184 (53.6) 63 (18.4) 0.767
CD3E Coeliac 1 118 (33.3) 178 (50.3) 58 (16.4)
rs3782042 G/A Control 1 133 (39.6) 158 (47.0) 45 (13.4) 0.196
CD3E Coeliac 1 158 (49.7) 131 (41.2) 29 (9.1)
rs1945764 T/C Control 1 155 (45.9) 160 (47.3) 23 (6.8) 0.223
CD3DG Coeliac 1 193 (54.4) 137 (38.6) 25 (7.0)
rs2276423 G/C Control 1 171 (49.9) 142 (41.4) 30 (8.8) 0.434
CD3DG Coeliac 1 240 (66.5) 109 (30.2) 12 (3.3)
rs3181259 G/A Control 1 238 (69.6) 97 (28.4) 7 (2.1) 0.469
CD3DG Coeliac 1 147 (41.9) 159 (45.3) 45 (12.8)
rs1561966 G/A Control 1 129 (38.2) 170 (50.3) 39 (11.5) 0.422
CD3DG Coeliac 1 187 (52.5) 139 (39.0) 30 (8.4)
rs7949185 T/C Control 1 183 (53.2) 132 (38.4) 29 (8.4) 0.983
THY1 Coeliac 1 161 (43.5) 171 (46.2) 38 (10.3)
rs1894006 G/A Control 1 161 (47.1) 155 (45.3) 26 (7.6) 0.380
THY1 Coeliac 1 122 (34.3) 173 (48.6) 61 (17.1)
rs1001205 G/A Control 1 127 (37.9) 160 (47.8) 48 (14.3) 0.468
IL18 Coeliac 1 145 (44.2) 147 (44.8) 36 (11.0)
rs2043055 A/G Control 1 116 (38.2) 156 (51.3) 32 (10.5) 0.244
IL18 Coeliac 1 154 (50.3) 135 (44.1) 17 (5.6)
* -137 rs187238 G/C Control 1 184 (54.6) 121 (35.9) 32 (9.5) 0.038
IL18 Coeliac 1 227 (75.7) 68 (22.7) 5 (1.7)
rs5744241 A/G Control 1 237 (82.3) 49 (17.0) 2 (0.7) 0.114
IL18 Coeliac 1 138 (36.6) 192 (51.1) 46 (12.2)
* -607 rs1946518 C/A Control 1 100 (31.1) 153 (47.5) 69 (21.4) 0.005
Coeliac 2 Vs Control 2
IL18 Coeliac 2 99 (57.9) 56 (32.7) 16 (9.4)
-137 rs187238 G/C Control 2 272 (52.7) 208 (40.2) 37 (7.1) 0.641
IL18 Coeliac 2 50 (42.4) 48 (40.7) 20 (16.9)
-607 rs1946518 C/A Control 2 201 (37.5) 256 (47.8) 79 (14.7) 0.712
Coeliac (1 + 2) Vs Controls (1 + 2)
IL18 Coeliac 253 (53.0) 191 (40.0) 33 (6.9)Brophy et al. BMC Medical Genetics 2010, 11:76
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0.0001). This is primarily due to the IL18-607C/-137C
haplotype, and the effect is detectable in the original case
control comparison (P = 0.00015, coeliac 1 Vs control 1,
Table 3), the follow up sample (P = 0.004, coeliac 2 Vs
control 2, Table 3), despite the limited size (N = 171) of
the coeliac 2 sample, and in the pooled case-control sam-
ple (P < 0.00001, Table 3). Furthermore, the values pre-
sented are corrected for the confounding effects of age
and sex. The P-values obtained for haplotype analysis are
presented without correction for multiple testing, but the
global tests (case-control 1, P = 0.00075; case control 2, P
= 0.0059; pooled case-control P < 0.00001) are significant
after correction for multiple testing across 6 gene regions.
Discussion
This candidate gene investigation of the chromosome 11
coeliac disease linkage region, which has been identified
by several linkage studies [1-3], contains analysis of six
genes;  CD3E,  CD3D,  CD3G,  IL10RA,  THY1  and  IL18.
Haplotype tagging strategies were used to define haplo-
types around the genes of interest, ensuring the maxi-
mum information content is gained. Polymorphisms
previously shown to be associated with disease or those
with a theoretical or proven functional role (e.g. gene
promoter regulation or transcription factor binding site
alteration) have been included where possible in this
study to provide as comprehensive a picture as possible of
the genetic variation present in these genes.
-137 rs187238 G/C Control 456 (53.4) 329 (38.5) 69 (8.1) 0.696
IL18 Coeliac 188 (38.1) 240 (48.6) 66 (13.4)
-607 rs1946518 C/A Control 301 (35.1) 409 (47.7) 148 (17.2) 0.042
P values (uncorrected for multiple testing) are for genotype heterogeneity (GENEPOP). SNPs with a reportedly functional role are marked with 
an asterisk (*).
Table 2: Comparison of genotypic frequencies (%) between Coeliac and Control samples (Table 1) and the pooled Coeliac 
(1 + 2) and Control (1 + 2) samples. (Continued)
Table 3: Haplotype frequencies in Coeliacs and Controls.
IL18-607 IL18-137 *Coeliac *Control Hap-Freq Hap-Score p-val sim p-val
Coeliac 1 Vs Control 1
A C 0.251 0.284 0.277 -0.717 0.473 0.467
A G 0.136 0.156 0.138 -0.776 0.443 0.438
C G 0.591 0.558 0.571 0.161 0.872 0.867
C C 0.022 0.002 0.014 4.056 0.00005 0.00015
Coeliac 2 Vs Control 2
A C 0.173 0.269 0.264 -1.231 0.218 0.241
A G 0.164 0.127 0.129 1.162 0.245 0.241
C G 0.591 0.597 0.597 -0.283 0.777 0.789
C C 0.072 0.007 0.009 3.139 0.002 0.004
Coeliac (1 + 2) Vs Control (1 + 2)
A C 0.234 0.275 0.271 -0.909 0.364 0.364
A G 0.142 0.138 0.134 0.577 0.564 0.566
C G 0.591 0.582 0.584 -0.630 0.529 0.531
C C 0.032 0.005 0.012 4.956 0.00001 0.00001
Case and Control haplotype frequencies were calculated using PHASE v2*. All other calculations were performed using HAPLOSTATS, and 
corrected for the effects of age and sex. P values are presented without correction for multiple testing. Haplotype IL18-607C/-137C is rare but 
confers risk (highly significant). Case 1 Vs Control 1, HAPLOSTATS global-stat = 16.880, df = 3, P < 0.00075. The same effect is evident when 
comparing coeliac 2 to control cohort 2, HAPLOSTATS global-stat = 12.49, df = 3, P = 0.0059. For comparison of pooled cases (1 + 2) Vs pooled 
controls (1 + 2), HAPLOSTATS global-stat = 25.620, df = 3, P < 0.00001, PHASE v2, overall P = 0.01, HITAGENE, P < 0.05.Brophy et al. BMC Medical Genetics 2010, 11:76
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Patterns of LD (Supplementary Figure S1, Additional
file 1) were generally consistent with those seen in the
CEPH European individuals in the Hapmap data, sug-
gesting the genes in question have been effectively
tagged. Linkage disequilibrium analysis of the 11q23
region showed that SNPs within each gene showed evi-
dence of LD with other SNPs in the same gene. However,
there was little to no inter-gene LD present, except in the
CD3 gene cluster. Thus the haplotype structure of each
gene was assessed separately for association with disease.
The promoter polymorphisms in IL18  were initially
f o u n d  t o  be  a s s oc i a t ed  w i t h  CD ,  be f o r e  c o r r ec t i o n  f o r
multiple testing. Analysis of follow-up samples suggested
that this first finding may be due to a haplotypic effect.
This is primarily due to the IL18-607C/-137C haplotype,
and the effect is detectable in the original case control
comparison, the follow up sample (despite the limited
size [N = 171] of the coeliac 2 sample) and in the pooled
case-control sample. Furthermore, the values presented
are corrected for the confounding effects of age and sex,
and remain significant when considering the effects of
multiple testing.
Candidate gene studies may yield conflicting results,
which may be due to population stratification, sampling
bias, inadequate sample size, variation in study design,
and mis-classification of phenotypes [40-42]. Population
stratification and sampling bias are unlikely to be an
issue, as all cases and controls were unrelated individuals
of ethnically uniform Irish origin. Power calculations [43]
indicate that our sample sizes afforded > 80% power to
detect an effect of genotype relative risk 1.3 for heterozy-
gotes and 1.6 for homozygotes for a range of allele fre-
quencies. While the effect size for IL18-607 was higher in
the first samples (coeliac 1 Vs control 1, genotype relative
risk 1.36 for heterozygotes and 1.84 for homozygotes), the
same comparison in the second (much smaller) set of
samples was not statistically significant. The combined
dataset was consistent with a weak effect for IL18-607
(genotype relative risk 1.16 for heterozygotes and 1.33 for
homozygotes). However, a much greater effect was
observed at the haplotype level, in both case-control sam-
ple sets independently and in the combined sample.
Using PLINK, we estimate the effect size of the IL18-607C/
-137C haplotype in our combined case-control sample to
have an odds ratio = 6.2; thus although rare, it is associ-
ated with a relatively large risk. Power calculations using
haplo.power.cc  (HAPLOSTATS) suggest that our sample
sizes afford > 95% power to detect a haplotypic effect of
odds ratio 3 or greater at the 5% level in both our case-
control samples, and the combined sample, consistent
with our observation of this effect in all three compari-
sons.
A previous study based on the TDT analysis [29] has
examined the relationship between IL18  and CD by
examination of these two promoter polymorphisms in
105 Spanish families, and found no association with dis-
ease. The differences between their result and ours may
reflect differences in study design and the rarity of the
IL18-137C/-607C  haplotype, the frequency of which is
unknown in Spain. It was not reported by Rueda et al [29]
for the Spanish population, but the control frequencies
observed by us are similar to those reported for the Ger-
man and Scottish populations [44].
Four of the 16 SNPs used in this study have been
included in a genome-wide analysis of coeliac disease risk
[4], where none showed association with disease. While
that study did include analysis of IL18-607 (rs1946518),
IL18-137  (rs187238) was not analysed. The haplotype
found in this study would not, therefore, have been
detected.
Interestingly, follow-up of the top 1500 positive results
from coeliac disease whole genome analysis [4] has pro-
vided robust replication of association with 7 loci, all of
which have a clear functional role in T-cell regulation
[35]. Furthermore, based on these findings it has been
calculated that non-HLA loci identified to-date contrib-
ute approximately 4% to the total CD risk, although this
may be an underestimate. Meanwhile, the contribution of
HLA-DQ2 and -DQ8 has been calculated at 35% [35].
Therefore, it is apparent that additional factors remain to
be discovered. While much of this missing heritability
may relate to low risk variants, it is likely that much of the
remaining variation may not be well detected by associa-
tion of single SNPs in the absence of reference to haplo-
types.
The observations that all the newly identified risk vari-
ants are associated with genes with a known role in a rele-
vant pathway, and that additional risk variants remain to
be uncovered, are highly pertinent in the context of
directed candidate gene analyses. This approach can be
applied to regions of known linkage to disease, and can be
f o c u s e d  o n  p a t h w a y s  ( e . g  T - c e l l  r e g u l a t i o n )  t h a t  a r e
known to be important in the aetiology of the disease. It
is of particular interest that one highly replicated non-
HLA CD risk modulator, the CTLA4 locus on chromo-
some 2q33 [45,46] was not detected in linkage studies or
the initial genome wide assocation study, although it has
since been significantly associated in a large combined
type 1 diabetes/coeliac disease study [47]
Conclusions
Our results suggest a possible haplotypic association
between SNPs in the IL18 locus and coeliac disease risk.
While this may represent a chance statistical departure
rather than a true disease association, the same relatively
rare haplotype has been noted in two independent rheu-
matoid arthritis populations [44]. Furthermore, the role
of IL18 as a CD candidate gene is further strengthened byBrophy et al. BMC Medical Genetics 2010, 11:76
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evidence to suggest that it plays a key role in the mainte-
nance of inflammation in active CD [48]. Directed candi-
date gene analyses, in combination with more indepth
analysis of haplotypic variation may still contribute to our
knowledge of complex disease risk, as many relevant
effects remain undetected. The 5q and 11q linkage
regions contain numerous un-investigated immune-
related genes, many of which are plausible candidate
genes for CD risk. These may form part of the next phase
of candidate gene studies in this condition.
Additional material
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